MDA5 Can Be Exploited as Efficacious Genetic Adjuvant for DNA Vaccination against Lethal H5N1 Influenza Virus Infection in Chickens

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Liniger, Matthias ^a   Summerfield, Artur ^a   Ruggli, Nicolas ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; ENZYME INHIBITOR; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 PROTEIN; PLASMID VECTOR; RETINOIC ACID INDUCIBLE PROTEIN I LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHICKEN; CLINICAL FEATURE; CLOACA; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG EFFICACY; GENE PRODUCT; IN VIVO STUDY; INFLUENZA A (H5N1); INNATE IMMUNITY; LOW DRUG DOSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTECTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYMPTOM; VIRUS SHEDDING;

ANIMALS; CHICKENS; DEAD-BOX RNA HELICASES; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; PLASMIDS; RNA, VIRAL; VACCINES, DNA;

AVIAN INFLUENZA VIRUS; GALLUS GALLUS; ORTHOMYXOVIRIDAE;

EID: 84870838643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049952     Document Type: Article

References (60)

1. Steel J, (2011) New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs 25: 285-298.
2. Horimoto T, Kawaoka Y, (2006) Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 12: 506-514.
3. Gasparini R, Amicizia D, Lai PL, Panatto D, (2012) Aflunov((R)): a prepandemic influenza vaccine. Expert Rev Vaccines 11: 145-157.
4. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742-1753.
5. Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, et al. (2011) Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One 6: e18577.
6. Vemula SV, Mittal SK, (2010) Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther 10: 1469-1487.
7. Yang SG, Wo JE, Li MW, Mi FF, Yu CB, et al. (2009) Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 27: 7451-7458.
8. Schwartz JA, Buonocore L, Suguitan A Jr, Hunter M, Marx PA, et al. (2011) Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 85: 4602-4605.
9. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, et al. (2011) Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 6: e16247.
10. Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, et al. (2008) Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3: e2432.
11. Gao Y, Wen Z, Dong K, Zhong G, Wang X, et al. (2012) Characterization of Immune Responses Induced by Immunization with the HA DNA Vaccines of Two Antigenically Distinctive H5N1 HPAIV Isolates. PLoS One 7: e41332.
12. Rao SS, Styles D, Kong W, Andrews C, Gorres JP, et al. (2009) A gene-based avian influenza vaccine in poultry. Poult Sci 88: 860-866.
13. Plotkin SA, (2005) Vaccines: past, present and future. Nat Med 11: S5-11.
14. Liniger M, Zuniga A, Naim HY, (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6: 255-266.
15. Laddy DJ, Weiner DB, (2006) From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 25: 99-123.
16. Tritto E, Mosca F, De Gregorio E, (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27: 3331-3334.
17. Leroux-Roels G, (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28Suppl 3: C25-36.
18. Tovey MG, Lallemand C, (2010) Adjuvant activity of cytokines. Methods Mol Biol 626: 287-309.
19. Xu R, Megati S, Roopchand V, Luckay A, Masood A, et al. (2008) Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 26: 4819-4829.
20. Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, et al. (2008) Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181: 3755-3759.
21. Lambrecht BN, Kool M, Willart MA, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29.
22. Coffman RL, Sher A, Seder RA, (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
23. Levitz SM, Golenbock DT, (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148: 1284-1292.
24. Kumar H, Kawai T, Akira S, (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388: 621-625.
25. Manicassamy S, Pulendran B, (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21: 185-193.
26. Olive C, (2012) Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 11: 237-256.
27. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197.
28. Johnston D, Zaidi B, Bystryn JC, (2007) TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 56: 1133-1141.
29. Moser M, Leo O, (2010) Key concepts in immunology. Vaccine 28Suppl 3: C2-13.
30. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
31. Kumagai Y, Takeuchi O, Akira S, (2008) Pathogen recognition by innate receptors. J Infect Chemother 14: 86-92.
32. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-737.
33. Seth RB, Sun L, Ea CK, Chen ZJ, (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682.
34. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167-1172.
35. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, et al. (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19: 727-740.
36. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, et al. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6: 981-988.
37. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S, (2008) Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 180: 683-687.
38. Kobiyama K, Takeshita F, Ishii KJ, Koyama S, Aoshi T, et al. (2009) A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J Immunol 182: 1593-1601.
39. Luo M, Qu X, Pan R, Zhu D, Zhang Y, et al. (2011) The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice. Vaccine 29: 2561-2567.
40. Luke JM, Simon GG, Soderholm J, Errett JS, August JT, et al. (2011) Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 85: 1370-1383.
41. Ireton RC, Gale M Jr, (2011) RIG-I like receptors in antiviral immunity and therapeutic applications. Viruses 3: 906-919.
42. Karpala AJ, Stewart C, McKay J, Lowenthal JW, Bean AG, (2011) Characterization of Chicken Mda5 Activity: Regulation of IFN-{beta} in the Absence of RIG-I Functionality. J Immunol 186: 5397-5405.
43. Liniger M, Summerfield A, Zimmer G, McCullough KC, Ruggli N, (2012) Chicken cells sense influenza A virus infection through MDA5 and CARDIF signaling involving LGP2. J Virol 86: 705-717.
44. Stevceva L, Abimiku AG, Franchini G, (2000) Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun 1: 308-315.
45. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, et al. (2011) Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol 156: 183-202.
46. Kumar S, Koul M, Rai A, (2010) Role of immunostimulatory molecules in poultry vaccines. Recent Pat Biotechnol 4: 235-241.
47. Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, et al. (2011) DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 19: 594-601.
48. Sarkar D, Desalle R, Fisher PB, (2008) Evolution of MDA-5/RIG-I-dependent innate immunity: independent evolution by domain grafting. Proc Natl Acad Sci U S A 105: 17040-17045.
49. Zou J, Chang M, Nie P, Secombes CJ, (2009) Origin and evolution of the RIG-I like RNA helicase gene family. BMC Evol Biol 9: 85.
50. Barber MR, Aldridge JR Jr, Webster RG, Magor KE, (2010) Association of RIG-I with innate immunity of ducks to influenza. Proc Natl Acad Sci U S A 107: 5913-5918.
51. Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, et al. (2008) Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A 105: 16743-16748.
52. Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, et al. (2009) PB2 protein of a highly pathogenic avian influenza virus strain A/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 83: 1572-1578.
53. Soda K, Sakoda Y, Isoda N, Kajihara M, Haraguchi Y, et al. (2008) Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res 55: 93-98.
54. Moulin HR, Liniger M, Python S, Guzylack-Piriou L, Ocana-Macchi M, et al. (2011) High interferon type I responses in the lung, plasma and spleen during highly pathogenic H5N1 infection of chicken. Vet Res 42: 6.
55. Ocana-Macchi M, Bel M, Guzylack-Piriou L, Ruggli N, Liniger M, et al. (2009) Hemagglutinin-dependent tropism of H5N1 avian influenza virus for human endothelial cells. J Virol 83: 12947-12955.
56. Schwarz H, Harlin O, Ohnemus A, Kaspers B, Staeheli P, (2004) Synthesis of IFN-beta by virus-infected chicken embryo cells demonstrated with specific antisera and a new bioassay. J Interferon Cytokine Res 24: 179-184.
57. Liniger M, Moulin HR, Sakoda Y, Ruggli N, Summerfield A, (2012) Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex. Virol J 9: 7.
58. Veits J, Romer-Oberdorfer A, Helferich D, Durban M, Suezer Y, et al. (2008) Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26: 1688-1696.
59. Mueller M, Renzullo S, Brooks R, Ruggli N, Hofmann MA, (2010) Antigenic characterization of recombinant hemagglutinin proteins derived from different avian influenza virus subtypes. PLoS One 5: e9097.
60. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, et al. (2002) Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40: 3256-3260.